To systematically identify and review the currently available evidence on the long-term outcomes of recommended attention-deficit hyperactivity disorder (ADHD) interventions following randomized controlled trials with children and young people. Method: A systematic search was conducted to identify trials .1 year in length using the following databases: CINAHL (January 1982-July 2012), MEDLINE (Ovid and Cambridge Scientific Abstracts [CSA]), Psych info, Science Direct (Elsevier), and Cochrane Library. Hand searches of key journals in the subject, book chapters, and conference proceedings were also carried out. Relevant papers were critically appraised using the Cochrane risk of bias tool. Results: Eight controlled trials were identified as being relevant, of duration ranging from 1 year to 8 years (at follow up). The total number of participants in the studies was 1,057, of whom 579 (54.7%) were from one cohort and included 26 different outcome measures. Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. Conclusion: This review has highlighted the paucity and limitations of the evidence investigating the long-term outcomes of recommended interventions for managing ADHD symptoms. There is little evidence to suggest that the effects observed over the relatively short term are maintained throughout longer periods of impairment. Furthermore, much of the existing evidence examining effectiveness beyond 12 months does not include newer medications currently available or consider significant contextual and cultural differences, such as UK/ European and Asian populations. Longitudinal studies are required to examine the long-term outcomes for children and young people with ADHD managed with currently recommended service interventions. They should also include the whole spectrum of ADHD, with its full range of coexisting conditions, and cultural and contextual diversity.
Background
Attention deficit hyperactivity disorder (ADHD) is a highly comorbid, 1−3 chronic neuropsychiatric disorder with a worldwide prevalence of around 5% of school age children, 4 of which up to 80% to 85% continue to be impaired by ADHD symptoms as adolescents 5−8 and up to 60% into adulthood.
Currently in the UK, ADHD is most commonly diagnosed between the ages of 6 and 12 years, 21 which is often a result of the impact the symptoms have on families, social lives, and academic attainment. 10 The long-term impact that untreated or poorly treated ADHD can have upon all aspects of the person with ADHD, their family, and importantly, their life chances, is profound. Therefore, the long-term monitoring of the effectiveness of service provision and clinical outcomes that cover the whole spectrum of ADHD is paramount. 9 
ADHD management
There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term. 22 However, although pharmacological treatments are relatively safe, these treatments are not without adverse side-effects, such as, suppression of growth, sleep problems, tiredness, loss of appetite, stomach upset, headaches, nausea, and increases in heart rate and blood pressure. 12,23−27 Nonpharmacological interventions, such as psychoeducational programs, behavioral interventions, and cognitive behavioral therapy are also recommended. 28−30 Although there is moderate-to-high-level evidence that nonpharmacological interventions can be effective in managing the core ADHD symptoms, conduct disorders, social skills, self-efficacy, and emotional outcomes at 6 months follow up, 28 little is known regarding the long-term effectiveness.
With increased awareness and more reliable diagnostic criteria, the number treated with medication in the UK has risen from 0.5 per 1,000 to over 3.0 per 1,000 over the last 30 years. 22 This has resulted in the number of prescriptions in the UK for stimulant medications increasing from 220,000 (1998) to 418,300 (2004) . 22 A UK cohort followed up after 5 years (ages [15] [16] [17] [18] [19] [20] [21] found that almost 69% of adolescents would still meet the criteria for ADHD, were still known to services, and exhibited high levels of antisocial behavior, criminal activity, and substance abuse. 31 However, despite the persistence of symptoms, the prevalence of prescribing and adherence to medication drops significantly from the age of 15 years. 32 This suggests that as children with ADHD move into adolescence and adulthood, their ADHD symptoms may not be managed optimally, resulting in negative repercussions on themselves, their family, and society.
ADHD is the most common reason for follow up by the UK Child and Adolescent Mental Health Services (CAMHS) 33 and can involve long-term monitoring throughout childhood, adolescence, and into adulthood. However, as a result of an often complex assessment and treatment process, inefficient methods of data collection, and difficulties tracking and monitoring long-term treatment, little is known regarding the long-term outcomes of those receiving recommended service intervention(s). 31, 33, 34 A recent review examined outcomes of individuals with ADHD in nine major outcome categories, and the effect of treatment or nontreatment. Studies of greater than 2 years duration published between 1980 and 2010 were included. They did not study core ADHD symptoms. They concluded that ADHD treatment may reduce but does not remove the negative effects of ADHD. 35 A further review looked at the effect of long-term (greater than 3 years) treatment on academic outcomes. This concluded that treatment of ADHD improved academic achievement scores but that the evidence for improved school grades was less convincing. The researchers discussed the difficulty in monitoring adherence to treatment in long-term studies and the effect this had on interpreting outcomes. 36 This review will therefore systematically examine the currently available evidence on long-term outcomes of treating children and young people with ADHD, with regards to symptom control and academic attainment.
Methods

Data sources and search strategy
A systematic search was conducted using the following databases: CINAHL (January 1982-July 2012), MEDLINE
Study selection
Sources of evidence were refined and limited to: 1. English-only retrievable papers; 2. Longitudinal studies (1 year); 3. Children/adolescents up to the age of 16 years; and 4. Where interventions involved parents, parents of children/adolescents, with children up to the age of 16 years. Studies were eliminated if they: 1. Were not randomized controlled trials (RCTs); 2. Involved children/adolescents with no definitive diagnosis of ADHD/hyperkinetic disorder (DSM IV or ICD 10); or 3. Included interventions that were not recommended in the National Institute for Health and Care Excellence (NICE) guidelines.
interventions
Studies were included if they involved interventions that are recommended in the NICE guidelines. 28 These are: parent education, social skills training, cognitive behavioral therapy, school/academic intervention, pharmacological intervention, and multimodal intervention(s). These were taken as currently recommended treatment strategies.
Outcome
This review focused on the methodological limitations of long-term randomized RCTs that have examined two key ADHD management issues; ADHD symptoms and academic achievement. The primary outcome for data extraction was ADHD symptoms. The secondary outcome was academic achievement.
Data extraction
Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources were screened independently by two review authors (JP/GW) to identify studies that potentially involved recommended interventions. The full text of these potentially eligible studies was retrieved and independently assessed for eligibility by two review authors (JP/GW). Any disagreements between them over the eligibility of particular studies were resolved through discussion with a third and fourth reviewer (NC/VH).
A standardized, pre-piloted form was used to extract data from the included studies, for assessment of study quality and evidence synthesis. Extracted information included: study setting; study population and participant demographics and baseline characteristics; details of the intervention and control conditions; study methodology; recruitment and study completion rates; outcomes and times of measurement; indicators of acceptability to users; suggested mechanisms of intervention action; information for assessment of the risk of bias. The four authors (JP/GW/NC/VH) extracted data independently; discrepancies were identified and resolved through discussion. Missing data was requested from study authors.
Critical appraisal
All twelve papers that fully met the eligibility criteria were evaluated against the Cochrane risk of bias tool 37 by the four review authors independently. This tool consists of twelve questions against which the study validity, methodological quality results, and external validity of each paper was evaluated. Each paper was assessed following the appraisal criteria, with a score out of 12 being allocated to each (see Table 1 ).
A study with a low risk of bias was deemed as one fulfilling six or more of the criteria items and with no fatal flaw, such as: 1. Drop-out rate .50%; and 2. Statistically and clinically signif icant differences between groups at baseline, indicating unsuccessful randomization. 47 Gillberg et al 48 The MTA 50 So et al 51 Jensen et al 52 The MTA 24 Volpe et al 49 Molina et al 53 was the method of randomization adequate? Intervention, Pharmacological Intervention, and Multimodal Intervention, with the key search terms (see above) eliminating 11,187 citations. A further 7,531 were eliminated, as they involved interventions that did not meet the inclusion/ exclusion criteria (see above), leaving 90 papers. Abstracts of the remaining 90 papers were scrutinized, and full papers of all citations where the methodology was unclear were accessed. This led to a further 73 citations being eliminated, leaving 17 papers, of which a further five were eliminated as they did not include the primary and secondary outcomes. 25,39−42 Those that achieved a score of less than 6 were also removed (four) but are described briefly below. Figure 1 depicts the study selection process.
38
Results
The four trials that met the inclusion criteria for this review but which fell beneath the risk of bias cutoff score were Abikoff et al; 43, 44 Hechtman et al; 45 and Charach et al, 46 scoring 5, 5, 5, and 3 respectively. With further description of the method of randomization and of whether treatment allocation was concealed, the studies by Abikoff et al 43, 44 and Hechtman et al, 45 would have met the risk of bias cutoff score. Nevertheless, these studies compared methylphenidate; methylphenidate and psychosocial intervention; and methylphenidate and attention control psychosocial treatment arms, in 7-to 9-year-old participants over a 2-year period (n = 103). They reported significant improvements in symptoms, social functioning, and academic achievement across all treatments and continued for 2 years. However, no advantage was found for any of the three treatment arms.
Charach et al 46 evaluated the impact of adherence and medication status on the effectiveness and adverse effects of stimulant use in children (aged 6-12 at baseline) with ADHD over 5 years (n = 88). They found that at 2 years, adherents (n = 41) showed greater improvements in teacher-reported symptom scores than those off medication (n = 16) and nonadherents on medication (n = 16) (P , 0.02). At 5 years, adherents (n = 16) showed greater improvements in teacher reported symptom scores than nonadherents on medication (n = 15) and those off medication (n = 14) (P , 0.04).
These findings are consistent with those trials using more robust methodological designs; however, because this trial fell well below the risk of bias cutoff score and because of the small sample size, the results should be interpreted with caution.
included papers
Of the eight remaining papers, five were separate studies, with four of the eight involving one cohort (in the multimodal treatment of children with ADHD [MTA] study) 25 
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The long-term outcomes of ADHD management followed up at 14, 24, 36, and 96 months. The eight papers were divided into three timescales: studies with outcomes between 12 to 18 months (four); studies with outcomes between 18 to 24 months (one); studies with outcomes between 24 months to 36 months (two); and finally, studies with outcomes over 36 months (one). This allowed for the methodological rigor to be examined over time. It is important to note that after the initial 14-month period in the MTA trial, the cohorts were no longer distinct. The longer-term follow-up studies are included despite this and demonstrate the difficulties with long-term studies. Table 1 displays the completed risk of bias tool consensus scores, in time order (shortest to longest). Table 2 provides a summary of the included studies, along with the age, sample size, intervention, study duration, outcome measures used, and the main results. Two of the studies involved pharmaceutical treatment only, 47, 48 one involved an academic intervention only, 49 and the remaining five included a combined pharmaceutical and behavioral management ("Comb") intervention, four of which were follow ups of the MTA study. 24,50−53 The age of the participants ranged from 6 to 11 years at baseline, and studies that included a behavioral component involved participants aged 7-9 50 and 7-9.9 years. 51 The total number of participants in the studies was 1,057, of which 579 (54.7%) were from the MTA. Furthermore, only one study other than the MTA measured outcomes beyond 18 months. 49 Five of the studies involved American cohorts; the other three studies involved cohorts in Europe, Israel, South Africa, and Australia.
Study characteristics
Studies with outcomes measured up to 18 months Medication
Two studies examined the use of medication only. 47 , 48 Gillberg et al 48 studied the effects of amphetamine on symptoms of ADHD over a 15-month active treatment period. Their double-blind multicentre (Sweden) RCT (n = 62) revealed that the treatment group obtained significantly lower Conners' Parent and Teacher Rating Scales outcomes than did the placebo group (P = 0.02). However, as a result of the difficulties in maintaining double-blind conditions for the 15-months treatment period, only 27% of the original cohort assigned to placebo completed randomized treatment through to month 15.
Buitelaar et al 47 carried out a double-blind multicentre (Europe -24 centers, South Africa -four centers, Israel -two centers, Australia -three centers) RCT (n = 163) to investigate the efficacy of atomoxetine in maintaining symptom response (preventing relapse) following 1 year of treatment. Using the ADHD Rating Scale IV (ADHD RS) as the primary outcome measure (described in DuPaul et al 54 ), they found that participants who initially responded during Attention-deficit hyperactivity disorder/ ADHD: citations identified n = 18,809 + key search terms: n = 11,187 remaining + Inclusion/exclusion criteria n = 90 remaining + Further clarification of inclusion/exclusion and methodology n = 17 remaining + Primary and/or secondary outcomes: n = 12 remaining Eliminated: Hechtman et al; 39 Molina et al; 40 Swanson et al; 25 Sayal et al; 41 Handen et al; 42 + Risk of bias ≥6: n = 8 remaining Eliminated: Abikoff et al; 43, 44 Hechtman et al; 45 Charach et al; 46 Refinement process 
94
Parker et al the acute phase (10 weeks) and continued treatment for 1 year were associated with outcomes that were superior to the control group at preventing relapse of symptom severity (P = 0.008) and symptom response (P = 0.001). Interestingly, they also found that a significant proportion of those randomized to switch from atomoxetine to placebo after a period of stable treatment for 1 year did not relapse during the 6-month follow up, suggesting that initial gains may be consolidated following a period of medication. However, natural selection bias, such as adverse effects, adherence/ protocol violations, as well as the length of time medicated and the gender ratio (9:1 male to female) may have limited the external validity of the results.
Multimodal
Two studies investigated the efficacy of Comb treatment over 14 months 50 and 18 months (6-month treatment phase with a 12-month follow up). 51 The MTA compared the efficacy of medication (careful titration followed by monthly visits) only ("Med Mgt"); intensive behavioral treatment only ("Beh"); Comb treatment; and standard community care provided by community providers ("CC"). The MTA behavioral intervention included intensive parent-, child-, and school-based interventions, based on previous work. Whilst all four groups showed significant improvement in all outcomes, those in the Med Mgt and Comb treatment groups showed significantly greater improvement (effect size 0.6) for ADHD symptoms than did the Beh treatment and CC groups (effect size 0.39) (P # 0.02). Whilst the study found insignificant difference between the Comb and Med Mgt for ADHD symptoms, the Comb treatment did show superiority for a number of outcomes, including social skills (using the Social Skills Rating System [SSRS]), reading, mathematics, and spelling (using the Wechsler Individual Achievement Test [WIAT] ). However, in light of the fact that two-thirds of the CC group in the MTA study were given medication but documented the least improvement, a Hong Kong-based study by So et al, 51 specifically compared Med Mgt (n = 41) with Comb treatment (n = 45). This trial also involved an intensive behavioral intervention which consisted of 24 weekly group session lasting approximately 100 minutes over a 6-month period. This included classroom management, skills training, and separate parent training sessions. Adherence was maintained in over 80% of participants in both treatment arms.
They found that at 6 months, the Comb group treatment arm was significantly more effective than Med Mgt for treating ADHD symptoms. However, at follow up (18 months), the Med Mgt group had caught up with the Comb group in improvement in ADHD symptoms.
Studies with outcomes measured between 18-36 months
Academic intervention Volpe et al 49 evaluated the effectiveness of an intensive data-based academic intervention (IDAI) with traditional data-based academic intervention (TDAI) implemented over 15 months (see Du Paul et al 60 and Jitendra et al, 61 for the specific intervention design). The IDAI differed from the TDAI in that consultants collaborated with classroom teachers to design academic interventions based on assessment data, treatment integrity, and the provision of feedback on progress, as opposed to academic interventions based on teacher choice and no feedback. At 1-year follow up, they found that significant improvement was only indicated in two of the 16 outcomes (reading and math fluency P , 0.01) for the IDAI group. However, in relation to the postintervention scores, students in both groups tended to maintain, although not necessarily improve upon, intervention gains. This highlights the need for sustained long-term intervention as these individuals progress through their education.
Multimodal
The MTA study group followed up their multimodal treatment study 50 at 24 months 24 and 36 months. 52 In the primary analysis, the main effect of assigned treatments was significant for ADHD symptoms (P , 0.0001) but not for social skills (P , 0.06) or reading (P , 0.38). The Comb and Med Mgt groups showed persisting superiority over the Beh and CC groups. However, additional benefits of Comb treatment over Med Mgt and of Beh over CC were not found. In addition, as a result of crossover, heterogeneity of choice within each treatment group, and compliance, the attenuation of effect size reduced from 0.6 (at 14 months) to 0.3 for ADHD
95
The long-term outcomes of ADHD management symptoms. The percentage of participants taking medication in the Beh and CC groups had also increased from 14% and 60% (at 14 months) to 38% and 62%, respectively.
At 3 years, in contrast to the findings at 24 months, 485 of the original 579 participants in the treatment groups did not differ significantly on any of the MTA outcome measures. The overall percentage of participants taking medication had increased by 50% over the 14-to 36-month time period, whereby the Beh group had increased from 14%-45%, the CC group remained constant, from 60%-62%, and the Med Mgt group had significantly decreased from 91% to 71%. The effect sizes for all of the treatment groups showed substantial improvement over baseline, with sizes of 1.6-1.7 for ADHD, 0.8-0.9 for social skills, and 0.1-0.2 for reading. Therefore, although the treatment groups that involved the medication algorithm showed initial superiority, this study suggests that at 36 months, all of the treatment interventions had positive outcomes. Importantly, after the initial strict groupings for 14 months, all participants were effectively receiving CC. However, the MTA also concluded that these findings may be a result of age-related decline in ADHD symptoms, changes in medication management and intensity, and compliance. In other words, by 36 months there was little difference between groups in terms of their treatment and symptoms.
Studies with outcomes measured beyond 36+ months Multimodal Only one paper 53 examining outcomes beyond 36 months met the review criteria. The MTA followed up the 14-, 24-, and 36-month outcomes with a prospective follow up of children treated within the original cohort(s) 50 at 6-8 years (n = 436). They also examined the functioning level of the original MTA participants in comparison with a local normative comparison group (n = 261). Their mixed-effects regression models revealed that the original randomized treatment groups did not differ from the 3-year results; 52 the ADHD symptom trajectory in the first 3 years predicted 55% of the outcomes; and the use of medication had decreased 62% after the initial 14-month randomization period. However, they concluded that despite initial 14-month treatment, the MTA group was still functioning less well than their non-ADHD age-matched controls, 6-8 years following the intervention.
Discussion
This review has highlighted the paucity of evidence and the limitations of examining the long-term outcomes of recommended interventions for managing ADHD symptoms.
Only eight papers met the criteria for this review, four of which involved the same cohort.
Existing studies examining the effectiveness of interventions suggest that relatively short-term interventions (,1 year), including Comb treatment (medication and Beh interventions), and Med Mgt are effective in treating ADHD symptoms, despite the level of severity. The findings of this review suggest that the effectiveness of recommended interventions may extend beyond 1 year and possibly up to 8 years albeit with reducing effect size, but the lack of continuing randomization makes these longer-term findings difficult to interpret. Additionally, as ADHD persists, those with the disorder will reach a similar level of functioning despite the initial level of severity or treatment provided, which will still be significantly below those without ADHD. For academic performance, those who receive Comb treatment 24,50−53 may improve academic performance, and the provision of a personalized, intensive classroom intervention may improve reading fluency. 51 However, this review has highlighted the limitations in applying existing evidence to the long-term impact ADHD can have on those affected.
Limitations of existing evidence
The definition of "long-term" and "treatment as usual" remains heterogeneous between studies. As there is no definitive explanation of these terms, difficulties remain in the evaluation of findings over time and of what exactly "treatment as usual" consists. We chose to include studies with greater than 1-year follow up. In general, studies examining the effects of treatments, both pharmacological and nonpharmacological, last up to 12 weeks. Other recent reviews looking at longer-term outcomes have included studies of over 2 years 35 or 3 years. 36 Evidence indicates that ADHD is a chronic disorder that spans from childhood through to adulthood. Therefore, the definition of longterm, when applied to relatively short periods of time (ie, 1 year), may be inappropriate within the context of ADHD, where "treatment as usual" may differ for younger to older service users. Secondly, it is well understood that each case of ADHD is unique in physical and functional impairments, possible comorbidities, and personal and environmental contextual factors. 11 In addition, each clinic may have varying models of service delivery and multidisciplinary teams. Therefore, evaluating the effectiveness of interventions against control arms where cases and clinics are not fully described becomes problematic. Thirdly, the studies included in this review have involved a number of countries 
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Parker et al (Table 2 ) and cultural backgrounds, such as, Caucasian, African American, Hispanic, 50 Chinese (Hong Kong), European, Israeli, South African, 47 and Swedish. 48 However, it should be noted that the vast majority of participants in these studies were western (US) Caucasian, and there is a distinct lack of evidence that includes UK, European, and Asian populations.
Whilst the trials in this review had adequate adherence to treatment rates and met the criteria for risk of bias dropout rates, it should be noted that some participants were switched to alternative medication as a result of efficacy or tolerability. For example, by the MTA study end, 212 (73.4%) of the 289 subjects given Med Mgt and Comb treatment were being successfully maintained on short acting methylphenidate, 30 (10.4%) on dextroamphetamine, four (1.4%) on pemoline, three (1.0%) on imipramine, one (0.3%) on bupropion, one (0.3%) on haloperidol, and 18 (3.1%) on no medication. Therefore, the results cannot be attributable to one form of medication alone, and as a result of clinical (ie, adverse side effects) and personal decisions (ie, a desire to withdraw), some participants were unable to adhere to long-term treatment arms. 62 Following their review of adverse events in studies lasting from 1 to 32 weeks, Aagaard and Hansen 63 concluded that there was a lack of good evidence about adverse effects during longterm medication use.
This review has exposed the plethora of outcome measures used between studies. The papers included in this review have used no fewer than 26 different outcome measures to examine the effectiveness of interventions. Whilst this in itself may underline the complexity of the disorder and the differences surrounding each case, there is very little explanation of comorbidity, cultural, and contextual issues beyond demographics that are known to impact on ADHD symptoms. 64 The limitation in methodological adherence is highlighted in Table 1 , whereby longer studies have a lower risk of bias score compared with shorter studies. However, it is clearly difficult to ethically avoid cointerventions over time, when further treatment is indicated. Whilst the MTA has become the mainstay of ADHD intervention effectiveness evaluation, this also became a naturalistic study after 14 months, 50 and although attempts were made to separate treatment modalities, unimodal therapy singular efficacy continues to be underresearched. Therefore the longer-term effect of recommended singular interventions remains questionable.
ADHD symptoms and its associated functional impairment(s) may change as a result of maturation as well as of changes in contextual conditions. 10 There are a number of studies that have explored the functional long-term outcomes of ADHD through childhood, adolescence, and into adulthood. These studies all indicate that long-term symptoms and functional impairment persist well into older years. 20,65−67 Indeed, functional impairment differs from childhood through to adulthood; for example, in school age children, hyperactivity, academic performance, and low self-esteem may be the focus of impairment. 10 In adults, the impairments surrounding substance abuse, social skills, and maintaining an occupation are associated with ongoing ADHD. 10 Therefore, the monitoring of impairment and symptom control throughout the life course of ADHD is paramount.
Despite ongoing clinical need and adult prevalence, as children move through adolescence and into adulthood, their adherence to treatment diminishes. 35 Therefore careful monitoring of adherence to treatment, symptom change, and impairment(s) throughout continued impairment is essential. However, there are few longitudinal studies that explore the effectiveness of interventions into adulthood and the link between intervention(s) provided, symptom severity, and functional impairment.
Research is required to explore the effectiveness of recommended interventions over the life course of ADHD, in other words, if intervention "x" is provided in childhood, how does this impact on adult impairment(s)? With advances in data management and technological applications for healthcare, 68 innovative models of service delivery and evaluation may overcome a number of the limitations associated with long-term research designs and monitoring of ADHD. 69 This review has not examined the role of comorbidities in long-term outcomes, although some data does exist. Within clinical practice, the majority of children/adolescents and adults have one or more comorbidities. [1] [2] [3] Cherkasova et al 70 recently reviewed the developmental course of ADHD and its predictors, demonstrating the negative impact of comorbidities. However, more research is needed in this area to reflect "real life" situations. Finally, we chose to only include interventions recommended by the NICE Guideline Group, using stringent evidence base. Gillies et al, 71 reviewed the use of polyunsaturated fatty acids in the treatment of ADHD and found no definite evidence of efficacy, and Lofthouse et al, 72 similarly failed to demonstrate conclusive benefit from neurofeedback. Further research may be helpful in examining the role of alternative therapies.
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The long-term outcomes of ADHD management
Conclusion
This review has highlighted the paucity of evidence and the limitations of examining the long-term outcomes of recommended interventions for managing ADHD symptoms. As a result of difficulty maintaining robust study design, the complexity of the disorder, and natural life course changes, there is little evidence to suggest that the effects observed over the relatively short-term are maintained throughout longer periods of impairment. Furthermore, much of the existing evidence examining effectiveness beyond 12 months does not include newer medications currently available, nor examine contextual and cultural differences, such as UK/European and Asian populations. Longitudinal studies examining the longterm outcomes of treating ADHD with currently recommended service interventions are needed, to plan and improve service delivery and patient outcomes. Long-term studies should include the whole spectrum of ADHD and coexisting disorders.
